This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Roche's Illumina Bid May Start War

Meanwhile, Roche's bid provided a windfall to Illumina competitors who are developing genetic sequencing machinery for research labs to study cancer tumors that may assist treatments for individuals as costs and sequencing times come down.

The stocks of Illumina's competitors Life Technologies (LIFE), Pacific Biosciences of California (PACB) and Complete Genomics (GNOM) surged roughly 3%, 15% and 23% respectively. Illumina and its competitors may bring sequencing time horizons down from weeks and even months to just a day, potentially lowering costs enough to make them increasingly affordable for patient care.

"[We] expect other stocks with direct exposure to sequencing (Life Technologies, Pacific Biosciences of California and Complete Genomics) will enjoy a sympathetic boost," wrote Leerink Swann analyst Dan Leonard in a note reacting to Roche's bid. However, Leonard tempers expectations of an M&A wave. "I don't think any of the companies I mentioned in the note are going to get an offer in a near term," said Leonard in a follow up conversation. Instead, he believes that Roche's interest is in Illumina cause for investors to reevaluate the growth prospects of the sequencing market.

Putting aside a potential new bidder for Illumina, Roche's bid could rise on simple valuation concerns. Jefferies analyst Jeffery Holford said in a Jan. 25 note that while Illumina's bid makes strategic sense, the $44.50 price is "opportunistic" and will likely need to be increased. JPMorgan analysts increased their price target for Illumina's shares by 60% to $70 a share, calling the bid too low for a technology leader in an open-ended market like genetic sequencing machinery.

"We believe the offer price underappreciates the [free cash flow] generation by the company," adds Wedbush Securities analyst Zarak Khurshid in a note upgrading Illumina's price target to $50 a share from $35.

Analysts currently give Illumina a price target of $41.91 a share, according to consensus estimates polled by Bloomberg. The company is expected to earn 28 cents in earnings per share when it reports its fourth quarter earnings on Jan. 31, according to estimates compiled by "Zacks. In its previous two quarters, Illumina missed Zacks consensus earnings estimates.

Presently, Roche is willing to pay a significant premium for Illumina's sequencing machinery, in spite of slowing earnings. The offer values Illumina at 32 times its 2012 profit estimates of $1.39 a share, according to Bloomberg. Nevertheless, that bid is below Illumina's historical three year average of 38 times earnings, making the firm's intrinsic value closer to $70 a share, according to William Blair analysts.

Illumina's board will now need to review Roche's offer and recommend action for shareholders, the company said in a statement. Goldman Sachs and Bank of America Merrill Lynch are acting as financial advisers to Illumina. Greenhill & Co. and Citigroup are Roche's financial advisers

-- Written by Antoine Gara in New York
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ILMN $139.45 3.00%
LIFE $3.98 -95.00%
AAPL $94.83 -0.19%
FB $101.52 1.80%
GOOG $692.62 1.40%


Chart of I:DJI
DOW 16,011.33 -15.72 -0.10%
S&P 500 1,847.92 -5.52 -0.30%
NASDAQ 4,276.1290 -7.6240 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs